AHA 2022 Rewind: Advancing Research and Driving Change in CV Disease

This past weekend was full of milestones for the Janssen Cardiovascular & Metabolism teams, as we presented new data in areas of critical unmet medical need across the cardiovascular (CV) disease space at the American Heart Association (AHA) Scientific Sessions 2022. Throughout the three-day conference in Chicago, IL, it was an all-hands-on-deck affair as we shared results and learned about other important CV research.

Many people know that CV disease, or heart disease, is the number one cause of death in the U.S. But our teams are drilling down into that statistic to uncover the causes that drive it and deliver innovative solutions that we hope will ultimately change it.

An area in which we’re pioneering innovative solutions is peripheral artery disease or PAD. Affecting 12 million Americans, PAD is a common circulatory condition that causes blood vessels to narrow, reducing blood flow to the limbs (often the legs) and bringing with it the hidden threat of amputation.1 Tragically, 70 percent of patients with PAD who have a leg amputation die within three years,2 and Black Americans – who are up to four times more likely than white Americans to undergo amputation as a result of PAD – are disproportionately affected.3 Data presented during two oral presentations on Monday revealed important insights into an important approach to treating PAD, and further reinforced the need to evolve the standard of care for patients managing CV diseases such as PAD and coronary artery disease (CAD).

I couldn’t be more proud of the work on display over the past several days. it exemplifies our passion and resolve to help save patients and their families from the impact of undiagnosed and untreated CV disease – including PAD – and reaffirms our role as a leader in innovation when it comes to CV treatment.

But the work doesn’t stop here. At Janssen, we won’t stop until we’ve created a future in which disease is a thing of the past.

#AHA22 #MyCompany ?#PeripheralArteryDisease #PAD

REFERENCES

1.???National Heart, Lung, and Blood Institute. Peripheral Artery Disease. Accessed October 2022 from https://www.nhlbi.nih.gov/health-topics/peripheral-artery-disease

2.???Jones WS, Patel M, et al. High mortality risks after major lower extremity amputation in Medicare patients with peripheral artery disease. Am Heart J. 2013 May;165(5):809-15, 815.e1. doi:10.1016/j.ahj.2012.12.002?

3.???Holman KH, Henke PK, Dimick JB, et al. Racial disparities in the use of revascularization before leg amputation in Medicare patients. J Vasc Surg. Accessed October 2022 from 2011;54(2):420-426. ?